Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Ma S, Li H, Zhou D, Zhang X, Shi M, Cao J, Qi Y, Xia J, Liu Y, Wang X, Li D, Sang W, Yan Z, Zhu F, Sun H, Cheng H, Zheng J, Xu K, Li Z, Qi K, Wang Y. Ma S, et al. Among authors: qi y, qi k. Cytotherapy. 2023 Jun;25(6):653-658. doi: 10.1016/j.jcyt.2023.01.011. Epub 2023 Mar 11. Cytotherapy. 2023. PMID: 36907717
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H, Cheng H, Qiao J, Wang Y, Wang Y, Gao L, Shi M, Sang W, Zhu F, Li D, Sun H, Wu Q, Qi Y, Li H, Wang X, Li Z, Liu H, Zheng J, Qian W, Zhang X, Xu K. Yan Z, et al. Among authors: qi y. Front Immunol. 2021 Feb 23;12:611366. doi: 10.3389/fimmu.2021.611366. eCollection 2021. Front Immunol. 2021. PMID: 33708205 Free PMC article.
Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
Zhang H, Yan Z, Wang Y, Qi Y, Hu Y, Li P, Cao J, Zhang M, Xiao X, Shi M, Xia J, Ma S, Qiao J, Li H, Pan B, Qi K, Cheng H, Sun H, Zhu F, Sang W, Li D, Li Z, Zheng J, Zhao M, Liang A, Huang H, Xu K. Zhang H, et al. Among authors: qi y, qi k. Front Immunol. 2022 Aug 19;13:965224. doi: 10.3389/fimmu.2022.965224. eCollection 2022. Front Immunol. 2022. PMID: 36059496 Free PMC article.
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, Cao J, Li D, Cheng H, Sang W, Zhu F, Sun H, Chen W, Qi K, Yan D, Qiu T, Qiao J, Yao R, Liu Y, Wang X, Zhang Y, Peng S, Huang CH, Zheng J, Li Z, Chang AH, Xu K. Xia J, et al. Among authors: qi y, qi k. J Clin Oncol. 2023 May 10;41(14):2583-2593. doi: 10.1200/JCO.22.01824. Epub 2023 Mar 7. J Clin Oncol. 2023. PMID: 36881785 Free PMC article. Clinical Trial.
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.
Ma S, Wang Y, Qi K, Lu W, Qi Y, Cao J, Niu M, Li D, Sang W, Yan Z, Zhu F, Cheng H, Li Z, Zhao M, Xu K. Ma S, et al. Among authors: qi y, qi k. Cancer Immunol Immunother. 2024 Apr 17;73(6):104. doi: 10.1007/s00262-024-03661-1. Cancer Immunol Immunother. 2024. PMID: 38630258 Free PMC article.
9,440 results